CNS lymphoma: A Critical review

CNS lymphoma: A Critical review

Abstract

CNS lymphoma is a rare form of the extra-nodal non-Hodgkin Lymphoma that is primarily confined to the brains, the eyes, and the cerebrospinal fluid without any existing knowledge or evidence of a systematic kind of spread[1].  The patient’s prognosis with the illness has, over time, improved notably during the last decade following the introduction of the higher doses of the methotrexate[2]. However, despite this new kind of progress, the result after the treatments are durable in half of the population of those suffering from the disorder.  The therapy can, however, be associated with considerably late neurotoxicity[3]. CNS lymphoma is considered an uncommon tumor, and only for a randomized trials in the way has been completed so far, all in the first timeline set[4].

Keywords: extra-nodal, non-Hodgkin, Lymphoma, neurotoxicity, tumor

Introduction

The CNS Lymphoma is considered a rare non-Hodgkin type of lymphoma in which the malignant or the cancer cells from the body lymphoid systems form in the brain and or in the spinal cord.  It can also spread to the other parts of the body[5].  Due to the fact the eye is also located next to the brain, the diseases can also start on the eyes, and this is called ocular lymphoma[6]. Cancer can also involve, in other cases, the spinal fluid that bathes the spinal cord and the brain. This type of lymphoma is termed as the leptomeningeal lymphoma.  Both, the primary and the secondary form of the lymphoma are very inhuman[7]. Because the diseases are very uncommon to but affect both men and women, the median diagnoses of the disorders stand at 55[8].

Methods

The methodology that will be used for this study includes the examination and review of the various healthcare journals and article which are related to the diseases. Because the condition is scarce, it becomes almost impossible to conduct a primary analysis or research from a patient suffering from the situation. The method will, therefore, do a review of the various secondary source to developed people understating of the condition[9].

Results

From the review of the various healthcare journals and articles on CNS lymphoma, the exact cause of the CNS lymphoma has not yet been established[10]. However, according to the various research conducted, it is believed that there are various factors that might increase the overall individual risk factor of the disease[11]. Such includes having a weak or compromised immunity as a result of the AIDS or as a result, an organ transplant, which might also reduce the freedom of an individual[12].

Discussion

Pathophysiology of CNS Lymphoma

Pathology does reveal very proliferative cancer cells in an angiogenetic kind of evolution formulae, verbosely sensitive the CNS[13]. Several of the CNS lymphoma forms are a sizeable diffuse form of B-cells lymphoma and are relay Burkitt, little score, or the T-cells lymphoma forms. Gene-expression profiling has, in the long run, acknowledged three molecular subsections of the nation CNS lymphoma[14]. This includes the germinal center B-cells, like activated B-cell has type 3 subgroups. The discoloration of the CNS operations with antibodies that works to differentiate the CNS subgroups did indicate that the most significant number of the CNS lymphoma forms were not germinal center subtype[15]. Outside, the CNS subgroups are linked with the worse outcomes and the common form of alterations in the B-cells pathway of receptors. In the same cohort, the B-cells receptor signaling axis with the downstream kind of targets is exaggerated by the actual frequency of the mutation that recur over some time and which are MYD88 and the CD79B.

Biochemistry of Lymphoma

The lymphatic system is one critical pay off the body’s immune system. It is made up of various parts, among them the spleen, tonsils, and the lymph nodes[16]. The organization also has a white blood cell that are referred to as the lymphocyte’s whole role is to fight the infections in the organs CNS. If the cells become cancerous, they can result in the lymphoma[17]. Lymphoma However, the diseases are rare in women than in men, and the prevalence is considerably higher for individuals suffering from AIDS[18] (Falautano et al., 2017).

Genetics of CNS Lymphoma

Hereditary lacerations additional precise for central CNS lymphoma comprise hypermutations and chromosomal movements, particularly those connecting the IgH and BCL-6 genes. TP53 changes are infrequent in CNS lymphoma[19]. The precise fundamental source of chief CNS lymphoma is not adequately understood; yet, individuals with a debilitated immune system or who have had a body part move look to have an enlarged peril of evolving the complaint[20] .

The clinical implication of CNS Lymphoma

Despite the fact, the CNS lymphoma is a rare condition and even more scare in women. The impact of the disease is very dire. If not adequately dealt with at the right time, the disorders are particularly important in the whole body weakness. They can affect the specific areas of the body[21]. The conditions are usually associated with severe, headaches, seizures, and problems which are related to the vision and the balance of the patient[22]. For most people, the symptom of the disease might include the inability to focus or concentrate on a given aspect of life[23].  The risk of developing a post-transplant lymphoma is higher due to the low immune system that is produced by such activities.  In this way, the disorder can result in the death of the patient, especially when the individuals are HIV positive (Panageas et al., 2015).

Scientific analysis of CNS Lymphoma

The paper was developed from the two major articles written by Panageas et al. (2015) and Karimi et al. (2013). The first article by Karimi et al., (2013) did highlight much information concerning the disorder but did little in answering the question concerning the treatment and the case of the disease[24]. However, the second article did much on the treatment of the CNS lymphoma. Preference was given to the second article by Karimi et al. (2013) over the first one since it is more detailed[25].

The unanswered question of CNS Lymphoma

The answered question which has not been answered about the CNS lymphoma is the actual cause of the disease[26]. With various research suggesting the various risk factors of the condition, the real cause of the disease remains a mystery.  most of the studies indicating the median age for individuals suffering from the disorders stand at 55 years[27]. The prevalence is considerably higher among those who have AIDS. However, the actual cause of the disease is not well known[28] .

Conclusion

The CNS lymphoma is a rare condition or the rare CNS neoplasm. It is, however highest incidence in the older adult and the immunocompromised persons, especially those suffering from the HIV/AIDS of persons who had transplantation of body organs[29]. In the past,  there exists a critical difference in the presentation and the evaluations of the immune-potent patients and those of the immunocompromised patients. The diagnostic pitfalls in this very uncommon tumor can often result in a missed or delayed diagnosis. This often results in delayed management or additional treatment of the disease[30]. Once it is initiated, therapeutic management most often centers on the systematic kind of chemotherapy. The disease, however, does not affect many people all over the world, and the real causal factor is yet to be established.

[1] Omuro, A., Correa, D. D., DeAngelis, L. M., Moskowitz, C. H., Matasar, M. J., Kaley, T. J., … & Panageas, K. S. (2015). R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplants for newly diagnosed primary CNS lymphoma. Blood, 125(9), 1403-1410.

[2] Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., … & Kadoch, C. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood, 121(5), 745-751.

[3] Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., … & Karimi, S. (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of Clinical Oncology, 31(31), 3971.

[4] Ferreri, A. J., Cwynarski, K., Palczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., … & Ambrosetti, A. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomization of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet Haematology, 3(5), e217-e227.

[5] Hoang-Xuan, K., Bessell, E., Bromberg, J., Hottinger, A. F., Preusser, M., Rudà, R., … & Cassoux, N. (2015). Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. The Lancet Oncology, 16(7), e322-e332.

[6] Rubenstein, J. L., Wong, V. S., Kadoch, C., Gao, H. X., Barajas, R., Chen, L., … & Kaplan, L. D. (2013). CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood, 121(23), 4740-4748.

[7] Korfel, A., & Schlegel, U. (2013). Diagnosis and treatment of primary CNS lymphoma. Nature Reviews Neurology, 9(6), 317.

[8] Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., … & Desai, J. V. (2017). Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer cell, 31(6), 833-843.

[9] Rubenstein, J. L., Hsi, E. D., Johnson, J. L., Jung, S. H., Nakashima, M. O., Grant, B., … & Kaplan, L. D. (2013). Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of Clinical Oncology, 31(25), 3061.

[10] Phillips, E. H., Fox, C. P., & Cwynarski, K. (2014). Primary CNS lymphoma. Current hematologic malignancy reports, 9(3), 243-253.

[11] Doolittle, N. D., Korbel, A., Lubow, M. A., Schorb, E., Schlegel, U., Rogowski, S., … & Muldoon, L. L. (2013). Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology, 81(1), 84-92.

[12] Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., … & Rohle, D. (2017). Ibrutinib unmasks the critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discovery, 7(9), 1018-1029.

[13] Korea, A., Thiel, E., Martus, P., Möhle, R., Griesinger, F., Rauch, M., … & Mergenthaler, H. G. (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12), 1242-1248.

[14] Taylor, J. W., Flanagan, E. P., O’Neill, B. P., Siegal, T., Omuro, A., DeAngelis, L., … & Hoang-Xuan, K. (2013). Primary leptomeningeal lymphoma: international primary CNS lymphoma collaborative group report. Neurology, 81(19), 1690-1696.

[15] Korea, A., Schlegel, U., Herrlinger, U., Dreyling, M., Schmidt, C., von Baumgarten, L., … & Martus, P. (2016). Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. Journal of Clinical Oncology, 34(15), 1757-1763.

[16] Yamashita, K., Yoshiura, T., Hiwatashi, A., Togo, O., Yoshimoto, K., Suzuki, S. O., … & Iwaki, T. (2013). Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and 18 F-fluorodeoxyglucose positron emission tomography. Neuroradiology, 55(2), 135-143.

[17] Doolittle, N. D., Korbel, A., Lubow, M. A., Schorb, E., Schlegel, U., Rogowski, S., … & Muldoon, L. L. (2013). Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology, 81(1), 84-92.

[18] Houllier, C., Choquet, S., Touitou, V., Martin-Duverneuil, N., Navarro, S., Mokhtari, K., … & Hoang-Xuan, K. (2015). Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology, 84(3), 325-326.

[19] Gregory, G., Arumugaswamy, A., Leung, T., Chan, K. L., Abikhair, M., Tam, C., … & Opat, S. (2013). Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro-oncology, 15(8), 1068-1073.

[20] Partovi, S., Karimi, S., Lyo, J. K., Esmaeili, A., Tan, J., & Deangelis, L. M. (2014). Multimodality imaging of primary CNS lymphoma in immunocompetent patients. The British journal of radiology, 87(1036), 20130684.

[21] Kickingereder, P., Sahm, F., Wiestler, B., Roethke, M., Heiland, S., Schlemmer, H. P., … & Radbruch, A. (2014). Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. American journal of neuroradiology, 35(8), 1503-1508

[22] Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Möhle, R., … & Wolf, H. H. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31(4), 846.

[23] Omuro, A., Chinot, O., Taillandier, L., Ghesquieres, H., Toussaint, C., Delwail, V., … & Huchet, A. (2015). Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomized phase 2 trial. The Lancet Haematology, 2(6), e251-e259.

[24] Mansour, A., Qandeel, M., Abdel-Razeq, H., & Ali, H. A. A. (2014). MR imaging features of intracranial primary CNS lymphoma incompetent immune patients. Cancer Imaging, 14(1), 22

[25] Illerhaus, G., Kasenda, B., Short, G., Egerer, G., Lamprecht, M., Keller, U., … & Hau, P. (2016). High-dose chemotherapy with autologous hemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. The Lancet Haematology, 3(8), e388-e397.

[26] Schob, S., Meyer, J., Gawlitza, M., Frydrychowicz, C., Müller, W., Preuss, M., … & Surov, A. (2016). Diffusion-weighted MRI reflects proliferative activity in primary CNS lymphoma. PLoS One, 11(8), e0161386.

[27] Chamoun, K., Choquet, S., Boyle, E., Houllier, C., Larrieu-Ciron, D., Al Jijakli, A., … & Soussain, C. (2017). Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology, 88(1), 101-102.

[28] Ferreri, A. J., Donadoni, G., Cabras, M. G., Patti, C., Mian, M., Zambello, R., … & Bruno-Ventre, M. (2015). High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. Journal of Clinical Oncology, 33(33), 3903-3910.

[29] Li, Z., Qiu, Y., Personett, D., Huang, P., Edenfield, B., Katz, J., … & Copland, J. A. (2013). Pomalidomide shows significant therapeutic activity against CNS lymphoma with a substantial impact on the tumor microenvironment in murine models. PLoS One, 8(8), e71754.

[30] Glass, J., Won, M., Schultz, C. J., Brat, D., Bartlett, N. L., Suh, J. H., … & Bokstein, F. (2016). Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology, 34(14), 1620